In today’s briefing:
- Pfizer Inc.: The Global Blood Therapeutics Acquisition & Other Drivers
- Splunk Inc: Enhancement Of The Partnerverse Program & Other Developments
- Under Armour Inc: Digital Strategy & Other Drivers
Pfizer Inc.: The Global Blood Therapeutics Acquisition & Other Drivers
- While operating in a difficult foreign exchange environment, Pfizer maintained a good operational performance in the second quarter and delivered an all-around beat, exceeding Wall Street expectations on all counts.
- The chance of a future variety that combines the severity of the original virus with the contagiousness of Omicron nevertheless persists.
- Among major updates, Pfizer went on to acquire Global Blood Therapeutics to strengthen its commitment to sickle cell disease.
Splunk Inc: Enhancement Of The Partnerverse Program & Other Developments
- Splunk had a robust set of results with a top-line outperformance and it also exceeded the operating margin and earnings expectations for the quarter.
- Positive consumer engagement was seen by the management with robust competitive win rates, good business momentum, and a high net retention rate.
- In spite of the solid top and bottom line, the total ARR and cloud ARR came short of management expectations.
Under Armour Inc: Digital Strategy & Other Drivers
- Under Armour’s brand strength helped the company deliver an all-around beat while navigating the present environment.
- The company’s financial performance has been decent as its wholesale revenue increased while the eCommerce revenue and direct-to-consumer revenue decreased.
- The company is planning to launch a new footwear platform, Kevin, that can change the landscape of athletic footwear.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
